Even though the exact cause of sporadic AD remains elusive, and there are currently no effective treatments to stop or reverse the progression of this uniquely human and age-related neurological disorder, anti-NF-kB and/or anti-miRNA strategies pose a realistically exploitable and readily available therapeutic approach for intervention of progressive degenerative processes in the CNS that may be genuinely useful in the clinical management of AD. Here, NFKB1 is linked to Alzheimer disease.